Ixico Regulatory News (IXI)

21 Jul 2006 07:00

Phytopharm PLC21 July 2006 Company Contact: U.K. Investor Relations Contact:Phytopharm plc Financial DynamicsDr Richard Dixey David Yates / Ben Atwell+44 7867 782000 +44 207 831 3113Dr Daryl Rees+44 1480 437 697www.phytopharm.com Board Appointment GODMANCHESTER, Cambridgeshire, U.K. (July 21 2006) - Phytopharm plc (LSE: PYM;NASDAQBB: PHYOF; PHYOY) ("Phytopharm") announces the appointment with immediateeffect of Dr Peter Robin Blower, former Director of New Neuroscience products atSmithKline Beecham as a non-executive Board Director of Phytopharm. Dr Blower (aged 58) has over 30 years experience in medicinal research anddevelopment with a strong background in the field of neuroscience. Dr Blowerjoined Beecham Research Laboratories in 1969 and rose to the position ofDirector of New Neuroscience products in 1996 before leaving in 2000 to form hisown consultancy company. He has been elected to Fellowship of the Royal Societyof Medicine and the Institute of Biology and has authored over 50 scientificpublications. He has a M.I.Biol from the Institute of Biology (1972), a PhD inPharmacology from the University of Aston (1977) and a DSc from the Universityof East London (1997). Commenting on the appointment, Mr Gordon Stevens, Chairman of Phytopharm, said;"This appointment adds further relevant experience and strength to our Board,particularly in the field of neurology. This follows the recent appointment ofSandy Morrison, former CEO of Lipton Ltd, a Unilever subsidiary. I am delightedthat Peter is joining us and look forward to confirming further Boarddevelopments in due course." Dr Blower is currently a director of Biophar Consulting Ltd and MinsterPharmaceuticals plc. There are no further details required to be disclosed underparagraph 9.6.13R of the Listing Rules or Disclosure Rule 3.1.2R. -ENDS- NOTES TO EDITORS Phytopharm plc Phytopharm is a pharmaceutical company with a plant extract division. Thepharmaceutical division is dedicated to the discovery and development of singlechemicals as prescription medicines and the plant extract division is focussedon the development of plant extracts as functional foods and veterinaryproducts. More information concerning Phytopharm's activities can be found on its website at http://www.phytopharm.com This information is provided by RNS The company news service from the London Stock Exchange